Glutamine
Glutamine is the amide of glutamic acid and the most abundant free amino acid in human blood. It is a nitrogen shuttle, a fuel for fast-dividing cells, and the residue whose supply falls first when the body is under severe stress.
- Molecular formula
- C5H10N2O3
- Molar mass
- 146.14 g/mol
- Residue mass, average
- 128.1307 Da
- Residue mass, monoisotopic
- 128.05858 Da
- pKa (α-COOH / α-NH₃⁺)
- 2.17 / 9.13
- Isoelectric point
- 5.65
- CAS number
- 56-85-9
Structure
- H
- C
- N
- O
- S
The 3D geometry represents the neutral experimental record; the pH control applies to the skeletal view.
The skeletal view begins with the zwitterion at pH 7.
Neutral, but polar
Converting the carboxylate of glutamate to a carboxamide removes the charge and leaves a side chain that donates and accepts hydrogen bonds. Glutamine is neutral at every pH a peptide will meet.
Long enough to reach
The two-methylene arm gives glutamine the same reach as glutamate. In binding sites it often makes the hydrogen bond that gives a receptor its specificity.
Charge and pH
No third ionisation
The amide does not ionise, so the curve has two steps and the isoelectric point falls at 5.65, between the two pKa values.
Nitrogen without charge
Glutamine carries two nitrogen atoms without carrying any charge. That combination is why the body uses it to move ammonia around safely.
Properties
| IUPAC name | (2S)-2,5-diamino-5-oxopentanoic acid |
|---|---|
| Three-letter code | Gln |
| One-letter code | Q |
| Class | Polar, uncharged |
| Dietary requirement | Conditionally essential |
| CAS | 56-85-9 |
| PubChem CID | 5961 |
| InChIKey | ZDXPYRJPNDTMRX-VKHMYHEASA-N |
| Formula | C5H10N2O3 |
|---|---|
| Molar mass | 146.14 g/mol |
| Residue mass, average | 128.1307 Da |
| Residue mass, monoisotopic | 128.05858 Da |
| Side chain | Carboxamide |
| pKa, α-carboxyl | 2.17 |
| pKa, α-amino | 9.13 |
| Isoelectric point | 5.65 |
| Hydropathy | -3.5 |
| Volume ų | 114 |
Genetic code and occurrence
Codons
- CAA
- CAG
Codons are written as mRNA; U is uracil.
| Frequency in proteins | 3.93% |
|---|---|
| Number of codons | 2 |
| Dietary requirement | Conditionally essential |
Role in peptides
Cyclisation at the N terminus
An N-terminal glutamine converts to pyroglutamate readily, losing ammonia and 17 Da. Several natural peptides carry a pyroglutamate cap for exactly this reason: it blocks aminopeptidases.
Deamidation
Glutamine deamidates to glutamate, adding 0.98 Da. It is slower than asparagine deamidation but follows the same chemistry and matters over long storage.
Polyglutamine
Expanded CAG repeats produce long glutamine tracts that aggregate. Huntington’s disease and several ataxias are caused by exactly this expansion.
Biological role
A nitrogen carrier
Glutamine moves amide nitrogen between tissues and donates it to purine, pyrimidine and amino sugar synthesis. Muscle releases it; gut, kidney and immune cells consume it.
Fuel for dividing cells
Enterocytes and lymphocytes use glutamine as a primary fuel. So do many tumour cells, which is why glutamine metabolism is an active target in cancer research.
Conditionally essential
Healthy adults make enough glutamine. In severe burns, major trauma or critical illness, demand can exceed supply, which is the basis for its use in clinical nutrition.
Not the same as glutamate
Glutamine and glutamate are often confused, including on supplement labels. They differ by one amide group and have entirely different roles.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| Critical illness nutrition | Glutamine supplementation was widely adopted in intensive care, then a large multicentre trial reported increased mortality in patients with organ failure. Guidance now restricts its use, which makes this a good example of a plausible mechanism overturned by a proper trial. | Well studied, cautionary |
| Gut barrier function | Glutamine is a fuel for intestinal cells and has been trialled for intestinal permeability and for short bowel syndrome. Results vary by setting and most trials are small. | Mixed |
| Exercise and immunity | Trials in athletes testing glutamine for post-exercise infection rates and recovery have been small and largely unconvincing. | Weak |
| Sickle cell disease | An oral glutamine preparation has regulatory approval in the United States for reducing acute complications of sickle cell disease. That is a licensed medicine with a defined indication. | Established |
These summaries describe research on amino acids and related molecules, not evidence for Aminos products. Aminos products are laboratory research reagents, not supplements or medicines.
Laboratory notes
Unstable in solution
Glutamine degrades in aqueous solution to ammonia and pyroglutamate, which is why cell culture media are often supplied with a dipeptide form instead of free glutamine.
Deamidation in storage
Expect slow conversion to glutamate, detectable as a +0.98 Da shift. Lower pH and lower temperature slow it.
N-terminal capping
If a peptide begins with glutamine, a pyroglutamate peak is likely. Whether that is a problem or a feature depends on the design.
No UV signal
Glutamine adds nothing at 280 nm.
References
Sources used for the data on this page.
- PubChem CID 5961: L-GlutamineIdentifiers, formula and physical data.
- pKa and pI values for the twenty amino acidsDepartment of Chemistry, University of Calgary.
Reference information only. This page describes the chemistry and biology of an amino acid. Nothing here is medical, nutritional or dosing advice. Aminos compounds are sold strictly for laboratory research use and are not medicines.